HomeBiosimilar Antibodies

Biosimilar Antibodies

Cat.No. Product Name Information Isotype
A2573 Carlumab (Anti-CCL2 / MCP1) Carlumab (Anti-CCL2 / MCP1) is a humanised monoclonal antibody targeting CCL2 with high affinity. Carlumab can be used in cancer research, particularly in prostate cancer. MW:145.5 KD. Human IgG1
A2316 Belimumab (Anti-TNFSF13B / BAFF / CD257) Belimumab (Anti-TNFSF13B / BAFF / CD257) is a human IgG1λ monoclonal antibody that inhibits B-cell activating factor (BAFF). Belimumab can be used for systemic lupus erythematosus (SLE) research. MW : 144.56 kDa. Human IgG1
A2328 Belantamab (Anti-TNFRSF17 / BCMA / CD269) Belantamab (Anti-TNFRSF17 / BCMA / CD269) is a humanized monoclonal antibody directed against the B-cell maturation antigen (BCMA) that can be used in the synthesis of an antibody-drug conjugate (ADC), Belantamab mafodotin. MW : 145.5 KD. Human IgG1
A2378 Rinucumab (Anti-PDGFRB / CD140b) Rinucumab (Anti-PDGFRB / CD140b) is an anti-platelet-derived growth factor receptor beta (anti-PDGFR-beta) monoclonal antibody and has a potential to study neovascular age-related macular degeneration. MW: 145.5 kD. Human IgG4SP
A2397 Clivatuzumab (Anti-MUC1) Clivatuzumab (Anti-MUC1) is a humanized anti-mucin monoclonal antibody targeting an epitope in the MUC1 antigen expressed in most pancreatic cancers. MW: 145.5 kD. Human IgG1
A2430 Pascolizumab (Anti-IL-4) Pascolizumab (Anti-IL-4) is a humanized anti-IL-4 monoclonal antibody. Pascolizumab has the potential for asthma research. MW: 145.5 kD. Human IgG1
A2517 Begelomab (Anti-DPP4 / CD26) Begelomab (Anti-DPP4 / CD26) is a monoclonal antibody targeting DPP-4/CD26. Begelomab can be used for the research of severe refractory idiopathic inflammatory myopathy. MW: 145.5 KD. Human IgG2SA
A2813 Anti-Amyloid Beta (CSIRO anti-amyloid Beta scFv) Anti-Amyloid Beta (CSIRO anti-amyloid Beta scFv) is a recombinant monoclonal antibody in a single chain fragment variable (scFv) against amyloid beta, has the potential to be used in Alzheimer's disease (AD) research. MW : 145.14 KD. Human IgG1
A3069 Tenatumomab (Anti-Tenascin C) Tenatumomab (Anti-Tenascin C) is a murine monoclonal antibody targeting tenascin-C. It has been used for Pretargeted Antibody Guided Radioimmunoresearch (PAGRIT), and delivering radionuclides to tumors via PAGRIT and direct 131Iodine labeling approach. MW :146.48 KD. Human IgG1
A2814 Cudarolimab (Anti-TNFRSF4 / OX40 / CD134) Cudarolimab (Anti-TNFRSF4 / OX40 / CD134) is an agonistic fully human anti-OX40 (tumor necrosis factor receptor superfamily member 4, TNFRSF4, CD134, OX40L receptor) with potential immune checkpoint inhibitory and antineoplastic activities. MW : 145.94 KD. Human IgG1
A3070 Marstacimab (Anti-TFPI) Marstacimab (Anti-TFPI) is a monoclonal antibody targeting tissue factor pathway inhibitor (TFPI). It can be used for the research of hemophilia. MW :142.94 KD. Human IgG1
A2815 Dalotuzumab (Anti-IGF1R / CD221) Dalotuzumab (Anti-IGF1R / CD221) is a recombinant humanized monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF1R) with potential antineoplastic activity. MW : 146.78 KD. Human IgG1
A3071 Anti-TGFb1 (NIS793) Anti-TGFb1 (NIS793) is a monoclonal antibody targeting TGF-β. It can be used in metastatic melanoma and non-small cell-lung cancer. MW :143.78 KD Human IgG1
A2816 Visilizumab (Anti-CD3) Visilizumab (Anti-CD3) is a humanized, non-Fc receptor (FcR)-binding IgG2 monoclonal antibody (MoAb) directed against CD3 with potential immunosuppressive activity. Visilizumab has the potential to be used for ulcerative colitis and Crohn's disease research. MW : 144.62 KD. Human IgG2SA
A3072 Zampilimab (Anti-TGM2 / Transglutaminase 2) Zampilimab (Anti-TGM2 / Transglutaminase 2) is a monoclonal antibody targeting transglutaminase 2 (TG2). It has potential application in renal transplant. MW :143.48 KD. Human IgG4SP
A2817 Anti-CD34 Anti-CD34 is a humanized monoclonal antibody against CD34 surface antigen on human stem cells. MW: 145.9 KD. Human IgG1
A3073 Etigilimab (Anti-TIGIT) Etigilimab (Anti-TIGIT) is an antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains). It can be used in treatment of advanced or metastatic solid tumors. MW :144.84 KD. Human IgG1
A2818 Felzartamab (Anti-CD38) Felzartamab (Anti-CD38) is a fully human monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. MW : 143.66 KD. Human IgG1
A2819 Mezagitamab (Anti-CD38) Mezagitamab (Anti-CD38) is a human, non-agonistic immunoglobulin G1 (IgG1) monoclonal antibody directed against the cell surface glycoprotein ADP-ribosyl cyclase 1 (CD38) with potential immunomodulating and antineoplastic activities. MW : 144.44 KD. Human IgG1
A3075 Tilavonemab (Anti-Tau) Tilavonemab (Anti-Tau) is a humanised antibody that targets tau. It can be used in the study of Alzheimer's disease. MW :146.06 KD. Human IgG1